Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Eli Lilly to Acquire Crispr Gene-Editing Biotech Verve in $1.3 Billion Deal Eli Lilly, the world’s most valuable pharmaceutical company, has announced a deal to acquire Verve Therapeutics, a pioneering biotech company focused on gene-editing therapies, for up to $1.3 billion. The move is part of Lilly’s ongoing strategy to expand its pipeline of experimental…